Management of Multiple Sclerosis through Customized Ayurvedic Approaches

Multiple sclerosis (MS) is a chronic immune-mediated demyelinating disorder of the central nervous system characterized by inflammatory demyelination and neurodegeneration. Acute relapses are commonly managed with high-dose corticosteroids; however, residual neurological deficits, fatigue, and psychological disturbances often persist. Integrative approaches may help enhance postrelapse functional recovery. A 22-year-old female presented with newly diagnosed relapsing MS, confirmed clinically and radiologically. Following standard corticosteroid therapy for acute relapse, she experienced persistent pain, stiffness, reduced mobility, muscular weakness, visual disturbances, and psychological distress. Neurological deficits included generalized stiffness, impaired strength, restricted mobility, and visual symptoms. Based on Ayurvedic assessment, the clinical presentation was correlated with Sarvanga Vatavyadhi , indicating systemic Vata involvement. Diagnosis of relapsing MS was established through clinical evaluation and neuroimaging. Ayurvedic diagnosis was based on Doṣa predominance, symptomatology, and disease stage assessment. After completion of corticosteroid therapy, a structured stage-wise Ayurvedic management protocol was initiated. The internal medications given are Dhanadanayanadi kwatha, Maha manjishtadi kwatha, Balarishta, Yogaraja guggulu, and Vata vidwasak rasa . Pañcakarma procedures done are Sarvāṅga Abhyanga , Svedana , Basti Cikitsā , Śirodhārā , and Netra Tarpana . Therapies were administered sequentially based on patient condition and therapeutic response. The patient demonstrated significant improvement in pain, stiffness, mobility, muscle strength, visual symptoms, and psychological well-being. Functional recovery was observed during follow-up without reported adverse events. This case highlights the potential role of early integrative Ayurvedic intervention in supporting functional recovery and improving quality of life in relapsing MS following acute relapse management. Larger controlled studies are needed to establish efficacy, safety, and reproducibility.